Our Financials & Outlook
DEAR SHAREHOLDERS & INVESTORS
The past year allowed us to focus our efforts on two essential objectives: achieving optimal results for our current projects and reshaping Valneva’s path as we approach our tenth year in operation as a specialty vaccine company.
Our Key Figures 2022
The 2022 financial results are marked by the wind-down of our COVID-19 activities and a recovery in the travel market.
SHAREHOLDER STRUCTURE (FEBRUARY 2023)
Our capital strategy
Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.
PETER BÜHLERChief Financial Officer
In 2023, Valneva expects further product sales growth as the travel market continues to recover.